Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 8;7(1):55-60.
doi: 10.1002/jgh3.12852. eCollection 2023 Jan.

Vonoprazan and high-dose amoxicillin dual therapy for Helicobacter pylori first-line eradication: A single-arm, interventional study

Soichiro Sue  1 , Masaaki Kondo  2 , Takeshi Sato  1 , Hiroyuki Oka  2 , Katsuyuki Sanga  1 , Tsuyoshi Ogashiwa  2 , Mao Matsubayashi  1 , Hiroaki Kaneko  1 , Kuniyasu Irie  1 , Shin Maeda  1
Affiliations

Vonoprazan and high-dose amoxicillin dual therapy for Helicobacter pylori first-line eradication: A single-arm, interventional study

Soichiro Sue et al. JGH Open. .

Abstract

Background: To date, no interventional trial has assessed the efficacy and safety of vonoprazan and high-dose (500 mg four times daily, 2000 mg/day) amoxicillin dual therapy in terms of Helicobacter pylori eradication. We explored whether this was an appropriate first-line treatment.

Methods: This prospective, dual-center, single-arm interventional study was performed in Japan. Twenty H. pylori-positive patients lacking any eradication history were treated with vonoprazan 20 mg twice daily and amoxicillin 500 mg four times daily (qid) for 7 days. Eradication was evaluated using a stool H. pylori antigen test. We evaluated safety using patient questionnaires. This study was registered in the jRCT database (jRCT031200128).

Results: The intention-to-treat and per-protocol eradication rates were 90% (95% confidence interval [CI] 68.3-98.8%, n = 20) and 94.4% (95% CI 72.7-99.9%, n = 18) respectively. No significant adverse event was recorded.

Conclusion: Vonoprazan/high-dose amoxicillin dual therapy can be a safe standard first-line therapy. We are now undergoing a randomized controlled trial comparing dual therapy and vonoprazan-based triple therapy.

Keywords: Helicobacter pylori; amoxicillin; dual therapy; vonoprazan.

PubMed Disclaimer

References

    1. Sue S, Shibata W, Maeda S. Helicobacter pylori‐induced signaling pathways contribute to intestinal metaplasia and gastric carcinogenesis. Biomed. Res. Int. 2015; 2015: 737621. - PMC - PubMed
    1. Lee YC, Chiang TH, Chou CK et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta‐analysis. Gastroenterology. 2016; 150: 1113–1124.e5. - PubMed
    1. Sue S, Maeda S. Is a potassium‐competitive acid blocker truly superior to proton pump inhibitors in terms of Helicobacter pylori eradication? Gut Liver. 2021; 15: 799–810. - PMC - PubMed
    1. Sue S, Ogushi M, Arima I et al. Vonoprazan‐ vs proton‐pump inhibitor‐based first‐line 7‐day triple therapy for clarithromycin‐susceptible Helicobacter pylori: a multicenter, prospective, randomized trial. Helicobacter. 2018; 23: e12456. - PubMed
    1. Furuta T, Yamade M, Kagami T et al. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori . Digestion. 2020; 101: 743–51. - PubMed